Aptose Biosciences rises on safety results from early-stage cancer therapy trial

Aptose Biosciences

12/02/2025 18:06

** U.S.-listed shares of drug developer Aptose Biosciences
 APTO.O   APS.TO  rise 21.57% to 31 cents
    ** Co says its first line combination treatment is safe and 
tolerable in patients with a type of blood cancer in an
early-stage trial  
    ** Co is testing its experimental drug tuspetinib in
combination with two other standard of care therapies 
    ** To date, four patients have received lowest dose (40 mg)
of the combination treatment 
     ** The once daily therapy is being developed to treat newly
diagnosed patients with a type of blood cancer who are
ineligible to receive induction chemotherapy
    ** Expects enrollment of 18-24 patients by mid-late 2025 
    ** In the last 12 months, the stock down 87.5%

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))